NL-OMON46198已完成2 期
Early identification of patients who benefit from palbociclib in addition to letrozole - Palbociclib and FES PET
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Patients with ER positive (i.e. >1% staining), HER2 negative metastatic breast cancer
- •2. Post-menopausal status
- •3. Adequate bone marrow and organ function
- •4. ECOG performance 0-2
- •5. Signed written informed consent
- •6. Able to comply with the protocol
- •7. Age >=18 years
排除标准
- •1. Life expectancy < 3 months
- •2. Evidence of central nervous system metastases
- •3. Presence of life-threatening visceral metastases
- •4. Prior use of CDK4/6 inhibitor
- •5. Use of estrogen receptor ligands including estrogens, fulvestrant or tamoxifen <6 weeks before study entry.
- •6. Use of other anticancer therapy < 2 weeks prior to start with palbociclib
- •7. Concurrent malignancy
- •8. Active cardiac disease or a history of cardiac dysfunction
研究者
相似试验
进行中（未招募）
1 期
Early identification of patients who benefit from palbociclib in addition to letrozoleEUCTR2015-004231-12-NLniversity Medical Center Groningen
已完成
2 期
Biomarker discovery study to identify patients with advanced urothelial cancer benefitting from pembrolizumab treatmenturinary tract cancerurothelial carcinoma10038364NL-OMON53077Erasmus MC, Universitair Medisch Centrum Rotterdam80
进行中（未招募）
1 期
Biomarker discovery study to identify patients with advanced urothelial cancer benefitting from pembrolizumab treatmentEUCTR2017-000976-27-NLErasmus MC Cancer Institute80
进行中（未招募）
1 期
Identification of patients with high probability of not or poorly responding to therapy with mycophenolic acid pro-drugs.Patients with a de novo kidney transplantationMedDRA version: 12.0Level: LLTClassification code 10023438Term: Kidney transplantEUCTR2009-014997-16-ATMedizinische Universität Wien, Abteilung für Nephrologie und Dialyse150
尚未招募
Unknown
Study to Identify and check Patients with Chronic Kidney Disease and ProteinuriaCTRI/2024/07/071759AstraZeneca AB